BioMarin is expanding its rare-disease commercial base around VOXZOGO and newer enzyme therapies while advancing its own long-acting CNP program, BMN 333; VOXZOGO revenue guidance was raised to at least $1 billion for 2026, and BMN 333 remains in development for achondroplasia.
This filing mostly formalizes an already-known settlement. The definitive agreement supersedes the binding term sheet announced on August 31, 2026, and the filing says its terms are consistent with that earlier deal. 〔0〕 That makes the event confirmation rather than a fresh strategic surprise.
BioMarin receives an economic claim on Ascendis’s competing CNP product, but gives up the litigation fight. Ascendis receives a worldwide license covering TransCon CNP/navepegritide/Yuviwel, while BioMarin collects 20% of U.S. net sales and 18% of sales in the European Union, Brazil and South Korea through May 2030. 〔1〕
The trade-off is strategic, not merely legal. BioMarin secures royalties and releases Ascendis from past infringement claims, but also covenants not to sue over the covered patent rights and agrees to regulatory non-interference. 〔2〕 That removes a costly uncertainty while allowing a potential competitor to develop and commercialize a CNP therapy that could matter in the same growth-disorder market as VOXZOGO and BioMarin’s BMN 333.
Bottom line: This is a clean legal resolution with an attractive royalty stream, but it is not new information and does not materially change BioMarin’s operating story beyond converting the announced settlement into a final agreement.
Read the original 8-K on SEC EDGAR ↗